140 related articles for article (PubMed ID: 18215605)
1. Heart failure disease management programs: a cost-effectiveness analysis.
Chan DC; Heidenreich PA; Weinstein MC; Fonarow GC
Am Heart J; 2008 Feb; 155(2):332-8. PubMed ID: 18215605
[TBL] [Abstract][Full Text] [Related]
2. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
3. Long-term cost-effectiveness of disease management in systolic heart failure.
Miller G; Randolph S; Forkner E; Smith B; Galbreath AD
Med Decis Making; 2009; 29(3):325-33. PubMed ID: 19147835
[TBL] [Abstract][Full Text] [Related]
4. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure.
Galbreath AD; Krasuski RA; Smith B; Stajduhar KC; Kwan MD; Ellis R; Freeman GL
Circulation; 2004 Dec; 110(23):3518-26. PubMed ID: 15531765
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of telephonic disease management in heart failure.
Smith B; Hughes-Cromwick PF; Forkner E; Galbreath AD
Am J Manag Care; 2008 Feb; 14(2):106-15. PubMed ID: 18269306
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of ED decision making in patients with non-high-risk heart failure.
Collins SP; Schauer DP; Gupta A; Brunner H; Storrow AB; Eckman MH
Am J Emerg Med; 2009 Mar; 27(3):293-302. PubMed ID: 19328373
[TBL] [Abstract][Full Text] [Related]
8. [Cost effectiveness of the use of spironolactone in the treatment of chronic heart failure].
Soto Alvarez J; González Vilchez F
An Med Interna; 2001 Aug; 18(8):421-5. PubMed ID: 11589080
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of long-term oxygen therapy for chronic obstructive disease.
Oba Y
Am J Manag Care; 2009 Feb; 15(2):97-104. PubMed ID: 19284806
[TBL] [Abstract][Full Text] [Related]
10. A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure.
Postmus D; Pari AA; Jaarsma T; Luttik ML; van Veldhuisen DJ; Hillege HL; Buskens E
Am Heart J; 2011 Dec; 162(6):1096-104. PubMed ID: 22137084
[TBL] [Abstract][Full Text] [Related]
11. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
Cowie MR; Marshall D; Drummond M; Ferko N; Maschio M; Ekman M; de Roy L; Heidbuchel H; Verboven Y; Braunschweig F; Linde C; Boriani G
Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
[TBL] [Abstract][Full Text] [Related]
12. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care.
Turner DA; Paul S; Stone MA; Juarez-Garcia A; Squire I; Khunti K
Heart; 2008 Dec; 94(12):1601-6. PubMed ID: 18450843
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism.
Vegter S; Perna A; Hiddema W; Ruggenenti P; Remuzzi G; Navis G; Postma MJ
Pharmacogenet Genomics; 2009 Sep; 19(9):695-703. PubMed ID: 19696696
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of left ventricular-assist devices in end-stage heart failure.
Hutchinson J; Scott DA; Clegg AJ; Loveman E; Royle P; Bryant J; Colquitt JL
Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):175-85. PubMed ID: 18248272
[TBL] [Abstract][Full Text] [Related]
18. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH).
Jaarsma T; van der Wal MH; Lesman-Leegte I; Luttik ML; Hogenhuis J; Veeger NJ; Sanderman R; Hoes AW; van Gilst WH; Lok DJ; Dunselman PH; Tijssen JG; Hillege HL; van Veldhuisen DJ;
Arch Intern Med; 2008 Feb; 168(3):316-24. PubMed ID: 18268174
[TBL] [Abstract][Full Text] [Related]
19. Do patients with heart failure need a case manager?
Annema C; Luttik ML; Jaarsma T
J Cardiovasc Nurs; 2009; 24(2):127-31. PubMed ID: 19242278
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach.
Hass B; Lungershausen J; Hertel N; Poulsen Nautrup B; Kotowa W; Liedgens H
Eur J Health Econ; 2009 Jul; 10(3):309-21. PubMed ID: 19101743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
